A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors

Molecular Cancer Therapeutics

Volumn 14, Issue 2, 2015, Pages 461-469

  Kendra, Kari L ^a   Plummer, Ruth ^b   Salgia, Ravi ^c   O'Brien, Mary E R ^d   Paul, Elaine M ^e   Benjamin Suttle, A ^e,g   Compton, Natalie ^f,h   Xu, Chun Fang ^f   Ottesen, Lone H ^f,i   Villalona Calero, Miguel A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b FREEMAN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CHICAGO   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

^g Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

^h MRC BIOSTATISTICS UNIT   (United Kingdom)

ⁱ EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME; PACLITAXEL; PAZOPANIB; SIMVASTATIN; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONSTIPATION; CYP2C8 GENE; DECREASED APPETITE; DIARRHEA; DISEASE ASSESSMENT; DIZZINESS; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; GENE; GENOTYPE; HAIR DISCOLORATION; HUMAN; HYPERTENSION; LIMB PAIN; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN ABSCESS; SOLID TUMOR; TACHYCARDIA; TREATMENT RESPONSE; VOMITING; BLOOD; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; LEUKOCYTE COUNT; MIDDLE AGED; NEOPLASMS; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; PYRIMIDINES; SULFONAMIDES;

EID: 84923373652     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0431     Document Type: Article

References (46)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
2. Majeti BK, Lee JH, Simmons BH, Shojaei F. VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. BMC Cancer 2013; 13:213.
3. Jantus-Lewintre E, Sanmartín E, Sirera R, Blasco A, Sanchez JJ, Tarón M, et al. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer 2011;74:326-31.
4. Tas F, DuranyildizD,OguzH, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 2006;16:405-11.
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
6. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
8. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
9. van der Graaf WTA, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib in metastatic soft tissue sarcoma (PALETTE): a randomized, double-blind, placebo controlled phase 3 trial. Lancet 2012;379: 1879-86.
10. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011;378: 1931-9.
11. Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011;30:134-41.
12. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010;28:49-55.
13. Scagliotti GV, Felip E, Besse B, von Pawel J,Mellemgaard A, Reck M, et al. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small cell lung cancer. J Thorac Oncol 2013;8: 1529-37.
14. Schiller JH, Lee JW, Hanna N, Traynor AM, Carbone DP. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancerwhohave failed at least two prior chemotherapy regimens. E2501. J Clin Oncol 26, 2008 (suppl; abstr 8014).
15. Schiller H, Flaherty KT, Redlinger M, Binger K, Eun J, Petrenciuc O, et al. Sorafenib combined with carboplatin/paclitaxel for advanced non -small cell lung cancer: a phase I subset analysis. J Clin Oncol 24, 2006 (suppl; abstr 7194).
16. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non -small cell lung cancer. J Clin Oncol 2010;28:1835-42.
17. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355:2542-50.
18. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004;22:2184-91.
19. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multi-kinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21.
20. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small cell lung cancer. J Clin Oncol 2010;28:3131-7.
21. Bocci G, Di Paolo A, Danesi R. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis 2013;16:481-92.
22. Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, et al. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med 2013;5:166ra3.
23. Burris HA III, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, et al. Phase I study of pazopanib in combinationwith paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther 2012;11:1820-8.
24. Du Bois A, Vergote I, Wimberger P, Ray-Coquard I, Harter P, Curtis LB, et al. Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in womenwith newly diagnosed, untreated, gynaecologic tumours: a phase I/ II trial of the AGO study group. Br J Cancer 2012;106:629-32.
25. Tan AR, Dowlati A, Jones SF, Infante JR, Nishioka J, Fang L, et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 2010;15:1253-61.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-16.
27. McKenney JM, Swearingen D, Di Spirito M, Doyle R, Pantaleon C, Kling D, et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 2006;46:785-91.
28. Mross K, Häring B, Holländer N, Mielke S, Behringer D, Massing U, et al. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial. Onkologie 2002;25:503-8.
29. Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non -small cell lung cancer. J Clin Oncol 2008;26:468-73.
30. Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2013;31:373-9.
31. Yamamoto R, Kaneuchi M, Nishiya M, Todo Y, TakedaM, Okamoto K, et al. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer. Cancer Chemother Pharmacol 2002;50:137-42.
32. Fruehauf JP, Alger B, Parmakhtiar B, Jakowatz JG, Bettis C, Chuang T, et al. A phase II single arm study of pazopanib and paclitaxel as first-line treatment for unresectable stage III and stage IV melanoma: interim analysis. J Clin Oncol 30, 2012 (suppl 1; abstr 8524).
33. Goodman V, Wang Q, Pandite L, Watkins PB. Incidence and management of hepatic toxicity in pazopanib-treated patients. Ann. Oncol 2010;21 Suppl 8;viii282.
34. Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol 2011;54:1237-43.
35. Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, et al. Pazopanibinduced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010;102:1371-7.
36. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008;47:463-74.
37. Xu CF, Xue Z, Bing N, King KS, McCann LA, deSouza PL, et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol 2012;23:2470-1.
38. Legha SS, Ring S, Papadopoulos N, RaberM, Benjamin RS. Aphase II trial of taxol in metastatic melanoma. Cancer 1990;65:2478-81.
39. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski E, et al. A phase II study of taxol in patients with malignant melanoma. Investig New Drugs 1991;9:59-64.
40. Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res 2004;14:63-6.
41. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 2002;25:283-6.
42. Kim KB, Sosman JA, Fruehauf JP, Linette GP,Markovic SN, McDermott DF, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012;30: 34-41.
43. Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, et al. Overproduction of VEGF165 concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 2004;123:1151-61.
44. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small cell lung cancer(LUME-Lung 1): a phase 3, double-blind, randomized controlled trial. Lancet Oncol 2014;15: 143-55.
45. Salama AKS. Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol 2013;7:137-49.
46. Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis 2013;5 Suppl 5:S579-92.